Evidence map›Paper›PMID 29317722›Full record

ArticleScientific reports2018

Loss of the Mitochondrial Fatty Acid β-Oxidation Protein Medium-Chain Acyl-Coenzyme A Dehydrogenase Disrupts Oxidative Phosphorylation Protein Complex Stability and Function.

Sze Chern Lim, Makiko Tajika, Masaru Shimura, Kirstyn T Carey, David A Stroud, Kei Murayama, Akira Ohtake, Matthew McKenzie

Abstract read
In one paragraph

Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. N-glycosylation Modification of CTSD Affects Liver Metastases in Colorectal Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Sze Chern LimCentre for Genetic Diseases, Hudson Institute of Medical Research, 3168, Melbourne, Australia.
Makiko TajikaDepartment of Metabolism, Chiba Children's Hospital, 266-0007, Chiba, Japan.
Masaru ShimuraDepartment of Metabolism, Chiba Children's Hospital, 266-0007, Chiba, Japan.
Kirstyn T CareyCentre for Cancer Research, Hudson Institute of Medical Research, 3168, Melbourne, Australia.
David A StroudDepartment of Biochemistry and Molecular Biology, Monash Biomedicine Discovery Institute, Monash University, 3800, Melbourne, Australia.
Kei MurayamaDepartment of Metabolism, Chiba Children's Hospital, 266-0007, Chiba, Japan.
Akira OhtakeDepartment of Pediatrics, Saitama Medical University, 350-0495, Saitama, Japan.
Matthew McKenzieCentre for Genetic Diseases, Hudson Institute of Medical Research, 3168, Melbourne, Australia. matthew.mckenzie@hudson.org.au.ORCID http://orcid.org/0000-0001-7508-1800

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Medium-chain acyl-Coenzyme A dehydrogenase (MCAD) is involved in the initial step of mitochondrial fatty acid β-oxidation (FAO). Loss of function results in MCAD deficiency, a disorder that usually presents in childhood with hypoketotic hypoglycemia, vomiting and lethargy. While the disruption of mitochondrial fatty acid metabolism is the primary metabolic defect, secondary defects in mitochondrial oxidative phosphorylation (OXPHOS) may also contribute to disease pathogenesis. Therefore, we examined OXPHOS activity and stability in MCAD-deficient patient fibroblasts that have no detectable MCAD protein. We found a deficit in mitochondrial oxygen consumption, with reduced steady-state levels of OXPHOS complexes I, III and IV, as well as the OXPHOS supercomplex. To examine the mechanisms involved, we generated an MCAD knockout (KO) using human 143B osteosarcoma cells. These cells also exhibited defects in OXPHOS complex function and steady-state levels, as well as disrupted biogenesis of newly-translated OXPHOS subunits. Overall, our findings suggest that the loss of MCAD is associated with a reduction in steady-state OXPHOS complex levels, resulting in secondary defects in OXPHOS function which may contribute to the pathology of MCAD deficiency.

Indexed as

Acyl-CoA DehydrogenaseCell RespirationCells, CulturedDNA, MitochondrialElectron Transport Chain Complex ProteinsFatty AcidsFibroblastsGene DeletionGene Knockout TechniquesGene TargetingHumansLipid Metabolism, Inborn ErrorsMitochondriaOxidative PhosphorylationProtein StabilityReactive Oxygen SpeciesAcyl-CoA DehydrogenaseDNA, MitochondrialElectron Transport Chain Complex ProteinsFatty AcidsReactive Oxygen Species

Identifiers

PMID29317722
PMCPMC5760697

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.